Glycopyrronium Medical Valley
Quick Facts About Glycopyrronium Medical Valley
Key Takeaways
- Maintenance treatment only: Glycopyrronium Medical Valley is for daily COPD maintenance, not for acute bronchospasm or asthma relief
- Once-daily dosing: Inhale one 44 microgram capsule at the same time each day using the supplied dry powder inhaler device
- Fast onset, long duration: Bronchodilation begins within 5 minutes and lasts approximately 24 hours
- Do not swallow capsules: The hard capsules are for inhalation only and must be used with the inhaler device
- Kidney function matters: Patients with severe renal impairment require monitoring; no dose adjustment needed for mild-to-moderate impairment
What Is Glycopyrronium Medical Valley and What Is It Used For?
Glycopyrronium Medical Valley is a long-acting muscarinic antagonist (LAMA) bronchodilator used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It contains glycopyrronium bromide 44 micrograms as an inhalation powder in hard capsules, inhaled once daily to keep the airways open and improve breathing.
Glycopyrronium Medical Valley belongs to a class of medicines known as long-acting muscarinic antagonists (LAMAs), sometimes also called long-acting anticholinergics. These medicines are a cornerstone of COPD treatment, recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) as first-line maintenance therapy for patients with persistent symptoms or a history of exacerbations. The active ingredient, glycopyrronium bromide, works by blocking muscarinic M3 receptors on the smooth muscle cells that surround the airways. When these receptors are blocked, the smooth muscle relaxes, the airways widen (bronchodilation), and airflow improves.
COPD is a chronic, progressive lung disease characterised by persistent airflow limitation. It includes conditions commonly known as chronic bronchitis and emphysema. COPD affects an estimated 384 million people worldwide, according to the Global Burden of Disease study, and it is the third leading cause of death globally (WHO, 2023). Symptoms include chronic cough, sputum production, and breathlessness, particularly during physical activity. Although COPD cannot be cured, maintenance treatment with bronchodilators like glycopyrronium significantly improves lung function, reduces symptoms, and decreases the frequency of exacerbations.
One of the key advantages of glycopyrronium bromide is its rapid onset of action. Unlike some other long-acting bronchodilators that may take 30 minutes or more to produce noticeable effects, glycopyrronium provides clinically significant bronchodilation within 5 minutes of inhalation, with a duration of approximately 24 hours. This makes it suitable for once-daily dosing, which can improve adherence to treatment. Clinical trials, including the GLOW1 and GLOW2 studies, have demonstrated that inhaled glycopyrronium 44 micrograms once daily significantly improves trough forced expiratory volume in one second (FEV1) compared with placebo, while also reducing rescue inhaler use and improving health-related quality of life.
Glycopyrronium Medical Valley is a maintenance medication taken every day to prevent symptoms. It is not intended for the relief of acute bronchospasm or sudden breathing difficulties. Always keep a short-acting bronchodilator (such as salbutamol) available for use as a rescue inhaler when needed.
How does glycopyrronium work?
In the lungs, the neurotransmitter acetylcholine binds to muscarinic receptors (primarily M3 subtype) on airway smooth muscle, triggering contraction and narrowing of the airways. In patients with COPD, cholinergic tone is often increased, contributing to bronchoconstriction and excess mucus secretion. Glycopyrronium bromide competitively and reversibly blocks these M3 receptors, preventing acetylcholine-induced bronchoconstriction. The drug demonstrates kinetic selectivity for the M3 receptor over the M2 receptor, which means it dissociates more slowly from M3 receptors, resulting in prolonged bronchodilation with minimal cardiac side effects.
After inhalation of the dry powder capsule, glycopyrronium is rapidly absorbed through the lungs, reaching peak plasma concentrations within 5 minutes. The absolute bioavailability is approximately 45% of the delivered dose. The drug is primarily excreted renally, with a terminal elimination half-life of 33 to 57 hours, supporting its once-daily dosing regimen.
Approved indications
Glycopyrronium Medical Valley is approved for the following indication:
- Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)
It is not approved for the treatment of asthma. The safety and efficacy of glycopyrronium in asthma patients have not been established, and anticholinergic bronchodilators are not considered appropriate monotherapy for asthma.
What Should You Know Before Taking Glycopyrronium Medical Valley?
Do not use Glycopyrronium Medical Valley if you are allergic to glycopyrronium bromide or any other ingredient. Use with caution if you have narrow-angle glaucoma, urinary retention, or severe kidney disease. Inform your doctor about all medical conditions and medications before starting treatment.
Before you begin treatment with Glycopyrronium Medical Valley, it is essential that your prescribing physician has a complete understanding of your medical history, current health conditions, and all other medications you are taking. Anticholinergic medications such as glycopyrronium can interact with certain conditions and drugs, and knowing this information helps ensure that the treatment is both safe and effective for you.
Contraindications
You must not use Glycopyrronium Medical Valley if you have a known hypersensitivity (allergy) to glycopyrronium bromide, or to any of the excipients listed in the capsule composition. Signs of an allergic reaction may include rash, itching, swelling of the face or throat, or difficulty breathing. If you experience any of these symptoms after taking glycopyrronium, stop using the medication immediately and seek medical attention.
Warnings and Precautions
Glycopyrronium Medical Valley should be used with particular caution in the following situations. Discuss these conditions thoroughly with your doctor before starting treatment:
- Narrow-angle glaucoma: Anticholinergic medications can increase intraocular pressure. If you have narrow-angle glaucoma or are at risk of developing it, your ophthalmologist and pulmonologist should coordinate your care. Report any symptoms such as eye pain, blurred vision, visual halos, or red eyes immediately.
- Urinary retention: Glycopyrronium can reduce bladder smooth muscle contraction, potentially worsening urinary retention. This is particularly relevant for men with benign prostatic hyperplasia (BPH). If you experience difficulty urinating, reduced urinary stream, or a sensation of incomplete bladder emptying, contact your doctor.
- Severe renal impairment: Glycopyrronium is primarily excreted by the kidneys. In patients with severe renal impairment (estimated glomerular filtration rate below 30 mL/min/1.73 m2), including those with end-stage renal disease requiring dialysis, glycopyrronium should be used only if the expected benefit outweighs the potential risk, and these patients should be closely monitored for adverse effects.
- Cardiovascular conditions: Anticholinergic effects may include increased heart rate. Patients with unstable ischaemic heart disease, heart failure (NYHA class III–IV), or a history of myocardial infarction in the preceding 6 months were excluded from clinical trials and should use glycopyrronium with caution.
- Paradoxical bronchospasm: As with other inhaled medications, glycopyrronium may in rare cases cause paradoxical bronchospasm (sudden worsening of breathing immediately after inhalation). If this occurs, discontinue glycopyrronium immediately, use your rescue inhaler, and seek medical attention.
Glycopyrronium Medical Valley is not indicated for the treatment of acute episodes of bronchospasm or sudden worsening of COPD. In the event of an acute attack, use your short-acting rescue inhaler (e.g. salbutamol). If symptoms do not improve, seek immediate medical attention or call your local emergency number.
Pregnancy and Breastfeeding
There are limited data on the use of glycopyrronium in pregnant women. Animal studies do not indicate direct harmful effects with respect to reproductive toxicity at clinically relevant doses. However, as a precautionary measure, glycopyrronium should preferably be avoided during pregnancy unless the potential benefit to the mother justifies the potential risk to the foetus. Your doctor will discuss the risks and benefits with you.
It is not known whether glycopyrronium bromide or its metabolites are excreted in human breast milk. Animal studies have shown excretion in milk. A decision must be made whether to discontinue breastfeeding or to discontinue glycopyrronium therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. Consult your doctor before using this medicine if you are breastfeeding.
Children and adolescents
Glycopyrronium Medical Valley should not be used in children and adolescents under 18 years of age. COPD does not normally occur in this age group, and the safety and efficacy of inhaled glycopyrronium have not been established in paediatric patients.
How Does Glycopyrronium Medical Valley Interact with Other Drugs?
The main interaction risk is with other anticholinergic (antimuscarinic) medicines, which can increase side effects like dry mouth, constipation, and urinary retention. Glycopyrronium can be safely combined with LABAs, inhaled corticosteroids, and short-acting bronchodilators. No significant interactions with cimetidine have been observed.
Drug interactions with inhaled glycopyrronium are generally fewer than with oral anticholinergic medications because the inhaled route delivers the drug directly to the lungs with relatively low systemic absorption. Nevertheless, understanding potential interactions is important for safe and effective treatment. Always inform your doctor and pharmacist about all medicines you are taking, including prescription drugs, over-the-counter preparations, and herbal supplements.
Major Interactions
The most clinically important interaction involves the concurrent use of glycopyrronium with other anticholinergic (antimuscarinic) medications. Co-administration can lead to an additive anticholinergic burden, increasing the risk and severity of anticholinergic side effects.
| Interacting Drug / Class | Effect | Severity | Recommendation |
|---|---|---|---|
| Other LAMA inhalers (tiotropium, umeclidinium, aclidinium) | Additive anticholinergic effects; increased risk of dry mouth, urinary retention, constipation, glaucoma | Major | Do not use concurrently. Use only one LAMA at a time. |
| Oral anticholinergics (oxybutynin, tolterodine, solifenacin) | Increased systemic anticholinergic burden; increased risk of constipation, urinary retention, confusion (especially in elderly) | Major | Avoid if possible. Monitor closely if combination is necessary. |
| Tricyclic antidepressants (amitriptyline, nortriptyline) | Additive anticholinergic effects; increased risk of cognitive impairment, dry mouth, constipation | Moderate | Use with caution. Monitor for anticholinergic side effects. |
| First-generation antihistamines (diphenhydramine, chlorpheniramine) | Additive anticholinergic and sedating effects | Moderate | Prefer second-generation antihistamines (e.g. cetirizine, loratadine). |
| Short-acting beta-2 agonists (salbutamol) | Complementary bronchodilation; no adverse interaction | Low | Safe to use as rescue medication alongside glycopyrronium. |
| LABAs (formoterol, salmeterol, indacaterol) | Additive bronchodilation via different mechanisms | Low | Combination is commonly used and well-tolerated in COPD. |
| Inhaled corticosteroids (budesonide, fluticasone) | No pharmacokinetic interaction | Low | Safe combination. Often used together per GOLD guidelines. |
Minor Interactions
In clinical pharmacology studies, co-administration of glycopyrronium with cimetidine (a cationic drug that competes for renal tubular secretion) resulted in a modest increase in total glycopyrronium exposure (AUC increased by 22%). This change is not considered clinically significant and no dose adjustment is required. Similarly, no clinically relevant interactions have been observed with commonly used COPD medications such as theophylline or systemic corticosteroids when used at standard doses.
Glycopyrronium is not metabolised by cytochrome P450 enzymes to a significant degree, which reduces the likelihood of metabolic drug interactions. The primary elimination route is renal excretion of unchanged drug, meaning that interactions involving hepatic drug metabolism are unlikely.
What Is the Correct Dosage of Glycopyrronium Medical Valley?
The recommended dose is one inhalation of a 44 microgram capsule once daily using the provided dry powder inhaler. Take it at the same time each day. No dose adjustment is needed for elderly patients or those with mild-to-moderate renal impairment. Do not exceed one capsule per day.
Correct dosing and proper inhaler technique are crucial for achieving the full therapeutic benefit of Glycopyrronium Medical Valley. The medicine is delivered as a dry powder in hard capsules that are placed in a specific inhaler device. The capsules must never be swallowed – they are designed exclusively for oral inhalation using the accompanying device. Each capsule contains a nominal dose of glycopyrronium bromide equivalent to 44 micrograms of glycopyrronium.
Adults
Standard Adult Dose
Dose: One capsule (44 micrograms glycopyrronium) inhaled once daily
Timing: At the same time each day, preferably in the morning
Device: Use only the provided dry powder inhaler
Maximum: Do not exceed one capsule (44 micrograms) in 24 hours
The capsules should be removed from the blister immediately before use. Do not store capsules outside the blister packaging, as exposure to moisture can affect the powder. After placing the capsule in the inhaler and piercing it, breathe in deeply and steadily through the mouthpiece. Hold your breath for 5–10 seconds after inhalation to allow the medication to deposit in the airways. Check that the capsule is empty after use; if powder remains, repeat the inhalation.
Children
Paediatric Use
Glycopyrronium Medical Valley is not recommended for use in children and adolescents under 18 years of age. COPD is not a paediatric condition, and the safety and efficacy of inhaled glycopyrronium have not been established in this population.
Elderly
Elderly Patients (65 years and older)
Dose: No dose adjustment required based on age alone
Note: Elderly patients are more likely to have decreased renal function. Kidney function should be assessed and patients with severe renal impairment (eGFR <30 mL/min) should be monitored closely.
Caution: Increased susceptibility to anticholinergic side effects (dry mouth, constipation, urinary retention, cognitive effects).
| Population | Dose | Adjustment Needed | Monitoring |
|---|---|---|---|
| Standard adult | 44 mcg once daily | None | Standard follow-up |
| Elderly (≥65 years) | 44 mcg once daily | None for age; assess renal function | Monitor renal function, anticholinergic effects |
| Mild renal impairment (eGFR 60–89) | 44 mcg once daily | None | Standard follow-up |
| Moderate renal impairment (eGFR 30–59) | 44 mcg once daily | None | Periodic renal function tests |
| Severe renal impairment (eGFR <30) | 44 mcg once daily | Use only if benefit outweighs risk | Close monitoring for adverse effects |
| Hepatic impairment | 44 mcg once daily | None (hepatic metabolism is minimal) | Standard follow-up |
Missed Dose
If you forget to take your daily dose of Glycopyrronium Medical Valley, take it as soon as you remember. However, if it is almost time for your next dose (i.e. within a few hours of the next scheduled inhalation), skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one. Taking more than the prescribed amount increases the risk of anticholinergic side effects without providing additional bronchodilation.
To help you remember, try taking your dose at the same time each day, ideally as part of your morning routine. Setting an alarm or using a medication reminder app may also be helpful.
Overdose
High doses of inhaled glycopyrronium may lead to anticholinergic signs and symptoms, including dry mouth, visual disturbances, increased heart rate (tachycardia), constipation, and difficulty urinating. In clinical studies, doses up to 8 times the recommended therapeutic dose were administered to COPD patients without significant safety concerns, suggesting a relatively wide safety margin. Nevertheless, if you suspect an overdose, contact your doctor or local poison control centre immediately. Supportive and symptomatic treatment should be provided as necessary.
What Are the Side Effects of Glycopyrronium Medical Valley?
Common side effects include dry mouth, nasopharyngitis (common cold), insomnia, and urinary tract infection. Uncommon effects include bladder obstruction, cough, and oropharyngeal pain. Rare but serious effects include paradoxical bronchospasm, acute narrow-angle glaucoma, and angioedema. Most side effects are mild and manageable.
Like all medicines, Glycopyrronium Medical Valley can cause side effects, although not everybody gets them. Most side effects observed in clinical trials were mild to moderate in intensity and generally did not require discontinuation of treatment. The side effects listed below are categorised by frequency, based on data from clinical trials involving over 2,000 patients treated with inhaled glycopyrronium bromide 44 micrograms once daily.
Understanding the likelihood and nature of possible side effects helps you make informed decisions about your treatment and know when to contact your healthcare provider. If you experience any side effect that concerns you, or if you notice effects not listed here, speak to your doctor or pharmacist.
Common Side Effects
- Dry mouth (xerostomia) – the most frequently reported side effect
- Nasopharyngitis (common cold symptoms)
- Insomnia (difficulty sleeping)
- Gastroenteritis (stomach and intestinal inflammation)
- Urinary tract infection
- Upper respiratory tract infection
- Dyspepsia (indigestion)
- Dental caries (tooth decay, associated with dry mouth)
Uncommon Side Effects
- Bladder outlet obstruction and urinary retention
- Cough
- Oropharyngeal pain (sore throat and mouth)
- Hypoaesthesia (reduced sensation/numbness)
- Rash
- Rhinitis (runny/stuffy nose)
- Musculoskeletal pain
- Peripheral oedema (swelling in limbs)
- Palpitations
Rare Side Effects
- Paradoxical bronchospasm (sudden worsening of breathing)
- Angioedema (severe swelling of face, lips, tongue, or throat)
- Hypersensitivity reactions (allergic reactions)
Very Rare / Post-Marketing Reports
- Acute narrow-angle glaucoma (eye pain, blurred vision, halos around lights)
- Pruritus (severe itching)
Managing Dry Mouth
Dry mouth (xerostomia) is the most commonly reported side effect of glycopyrronium, consistent with its anticholinergic mechanism of action. While usually mild, persistent dry mouth can lead to secondary complications such as dental caries, oral candidiasis (thrush), and difficulty swallowing. Strategies to manage dry mouth include sipping water frequently throughout the day, using sugar-free chewing gum or lozenges to stimulate saliva production, practising good oral hygiene with fluoride toothpaste, and informing your dentist about your medication so that preventive dental care can be optimised.
When to Seek Immediate Medical Attention
Contact your doctor immediately or seek emergency medical care if you experience:
- Sudden worsening of breathing after inhalation (paradoxical bronchospasm)
- Swelling of the face, lips, tongue, or throat (angioedema) – this is a medical emergency
- Eye pain, blurred vision, or visual halos (possible acute narrow-angle glaucoma)
- Inability to urinate despite feeling the need (urinary retention)
- Chest pain, rapid or irregular heartbeat
Reporting Side Effects
If you experience any side effects, including those not listed here, talk to your doctor or pharmacist. You can also report side effects to your national medicines regulatory authority. In the EU, reports can be made through the national reporting system listed on the European Medicines Agency (EMA) website. Reporting side effects helps to improve knowledge about the safety of medications and contributes to ongoing pharmacovigilance efforts.
How Should You Store Glycopyrronium Medical Valley?
Store Glycopyrronium Medical Valley in the original blister packaging below 25°C. Protect from moisture. Only remove a capsule from the blister immediately before use. Keep out of the sight and reach of children. Do not use after the expiry date.
Proper storage of Glycopyrronium Medical Valley is essential to ensure the medication remains effective and safe to use. The inhalation powder capsules are sensitive to moisture, which can affect the delivery of the dry powder and reduce the inhaled dose. Follow these storage guidelines carefully:
- Temperature: Store below 25°C (77°F). Do not freeze.
- Moisture protection: Keep the capsules in the original blister packaging until immediately before use. Do not store loose capsules in the inhaler device or any other container.
- Light: Protect from excessive direct sunlight.
- Children: Keep out of the sight and reach of children.
- Expiry: Do not use after the expiry date stated on the carton and blister. The expiry date refers to the last day of that month.
- Inhaler device: Keep the inhaler clean and dry. Replace the inhaler device as directed in the product information.
Do not dispose of medications via wastewater or household waste. Return unused or expired medicines to your pharmacy for safe disposal. These measures help protect the environment and prevent accidental exposure.
What Does Glycopyrronium Medical Valley Contain?
Each hard capsule contains glycopyrronium bromide equivalent to 44 micrograms of glycopyrronium as the active ingredient. The capsule also contains lactose monohydrate as an excipient. The capsule shell is made of hypromellose (HPMC).
Understanding the full composition of your medication is important, particularly if you have known allergies or intolerances to specific ingredients. Below is a detailed breakdown of the contents of Glycopyrronium Medical Valley inhalation powder capsules.
Active Ingredient
The active substance is glycopyrronium bromide. Each hard capsule contains glycopyrronium bromide equivalent to 44 micrograms of glycopyrronium (delivered dose). Glycopyrronium bromide is a quaternary ammonium compound with limited ability to cross the blood-brain barrier, which minimises central nervous system side effects compared with tertiary amine anticholinergics.
Inactive Ingredients (Excipients)
- Lactose monohydrate: Used as a carrier for the inhalation powder to aid in the uniform delivery of the active drug to the lungs. The capsule contains a small amount of lactose, including milk protein. Patients with rare hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
Capsule Shell
- Hypromellose (HPMC): Forms the hard capsule shell. HPMC capsules are used because they are less sensitive to moisture than gelatin capsules, which is important for dry powder inhalers.
Glycopyrronium Medical Valley capsules contain lactose monohydrate, which may include trace amounts of milk protein. If you have a severe milk protein allergy (not the same as lactose intolerance), consult your doctor before using this medication. The amount of lactose per capsule is very small and is unlikely to cause problems in patients with lactose intolerance.
Frequently Asked Questions About Glycopyrronium Medical Valley
Glycopyrronium Medical Valley is a long-acting inhaled bronchodilator (LAMA) used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It helps relax the muscles around the airways, making breathing easier. It is taken once daily and is not meant for sudden breathing problems – always keep a short-acting rescue inhaler available.
Remove one capsule from the blister immediately before use. Place it in the dry powder inhaler device, close the chamber, and press the buttons to pierce the capsule. Breathe out fully (away from the inhaler), then place the mouthpiece between your lips and breathe in deeply and steadily. Hold your breath for 5–10 seconds. Open the chamber to check the capsule is empty; if not, repeat the inhalation. Never swallow the capsules.
The most common side effects are dry mouth, nasopharyngitis (common cold), insomnia, gastroenteritis, and urinary tract infection. Dry mouth is the most frequently reported effect and is related to the drug's anticholinergic mechanism. Most side effects are mild and tend to improve over time. Contact your doctor if any side effect is severe or persistent.
Yes, glycopyrronium can be safely combined with long-acting beta-2 agonists (LABAs), inhaled corticosteroids (ICS), and short-acting rescue inhalers. However, you should not use it together with other long-acting muscarinic antagonists (LAMAs) such as tiotropium, aclidinium, or umeclidinium, as this increases the risk of anticholinergic side effects without added benefit.
If you miss a dose, take it as soon as you remember unless it is almost time for the next dose. Never take a double dose. Try to establish a routine by taking your inhalation at the same time each day. Setting a daily alarm or using a medication reminder app can help ensure you don't miss doses.
Yes, glycopyrronium can be used in elderly patients at the standard dose of 44 micrograms once daily. No dose adjustment is needed based on age. However, elderly patients should have their kidney function checked, as impaired renal clearance can increase drug exposure. They should also be monitored for anticholinergic side effects such as dry mouth, urinary retention, and constipation.
References
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD. 2024 Report. Available at: goldcopd.org
- European Medicines Agency (EMA). Glycopyrronium bromide – Summary of Product Characteristics (SmPC). EMA/CHMP assessment reports.
- D'Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respiratory Research. 2011;12:156. doi:10.1186/1465-9921-12-156
- Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. European Respiratory Journal. 2012;40(5):1106–1114. doi:10.1183/09031936.00040712
- World Health Organization (WHO). Chronic Obstructive Pulmonary Disease (COPD) Fact Sheet. Updated 2023. Available at: who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
- Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. The Lancet Respiratory Medicine. 2022;10(5):447–458. doi:10.1016/S2213-2600(21)00511-7
- Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. International Journal of COPD. 2012;7:503–513. doi:10.2147/COPD.S32451
- British National Formulary (BNF). Glycopyrronium bromide (inhaled). bnf.nice.org.uk
Editorial Team
This article has been written, fact-checked, and medically reviewed by the iMedic Medical Editorial Team according to our strict editorial standards.
iMedic Medical Writers
Specialists in pulmonary medicine and clinical pharmacology
iMedic Medical Review Board
Board-certified physicians following GOLD and EMA guidelines
Level 1A – Based on systematic reviews and randomised controlled trials (GRADE framework)
Next review scheduled within 12 months